Enterprise value to EBITDA forward of Surgery Partners, Inc. – NASDAQ:SGRY
This article provides the enterprise value to EBITDA forward for Surgery Partners, Inc. (NASDAQ: SGRY). It is a brief financial snippet from TradingView, indicating that the data is presented without further elaboration.
Enterprise value to EBIT forward of Surgery Partners, Inc. – NASDAQ:SGRY
The article discusses the enterprise value to EBIT forward for Surgery Partners, Inc. (NASDAQ: SGRY). It appears to be a financial data snippet from TradingView, indicating a specific financial metric for the company. The content itself is very brief and seems to be a placeholder or partial data display rather than an analytical article.
Enterprise value to EBIT forward of Surgery Partners, Inc. – DUS:1SP
This article provides financial information for Surgery Partners, Inc. (DUS:1SP) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBIT forward. It indicates that the market is currently closed with no trades. The content is presented without further elaborating on the specific financial figures or analysis.
SGRY - Surgery Partners Inc Latest SEC Filings
This article provides a detailed financial overview of Surgery Partners Inc (SGRY), including its latest stock performance, key financial metrics, valuation ratios, and ownership details. It highlights the company's recent stock close, percentage change, and various profitability and efficiency ratios. The data also covers analyst recommendations and price targets, offering a comprehensive snapshot of SGRY's market position.
Why Surgery Partners (SGRY) Stock Is Trading Up Today
Shares of healthcare company Surgery Partners (SGRY) rose by 2.7% following Cantor Fitzgerald's reiteration of an "Overweight" rating and an $18.00 price target. Despite some negative trends in Q2 data acknowledged by the analyst, the overall outlook for the company remains positive, with profitability expected this year. The stock, currently trading at $17.15, is up 12.4% year-to-date, though it remains below its 52-week high from August 2025.
Surgery Partners stock rating maintained at Overweight by Cantor
Cantor Fitzgerald has reiterated its Overweight rating for Surgery Partners (NASDAQ:SGRY) and maintained an $18.00 price target. Despite slight negative trends in Q2 2026 for ambulatory surgery centers and outpatient nursing, the firm noted these were not significant enough to indicate broad hiring pressure. Analysts predict profitability for Surgery Partners this year, with expected net income growth.
Cantor Fitzgerald reiterates Surgery Partners stock rating at Overweight
Cantor Fitzgerald has reiterated its Overweight rating on Surgery Partners (NASDAQ:SGRY) with a price target of $18.00, despite the stock being slightly overvalued according to InvestingPro data. The firm's analysis indicates less optimistic views on outpatient pricing step-up than consensus. Investors are focusing on the recovery of pressure facilities and the upcoming 2026 Investor Day, which is expected to include portfolio updates. Analysts also predict the company will achieve profitability this year with an EPS forecast of $0.43.
Enterprise value to revenue forward of Surgery Partners, Inc. – FWB:1SP
This article provides the enterprise value to revenue forward for Surgery Partners, Inc. (FWB:1SP). It lists basic financial information available on TradingView for the company. The content appears to be a stub or a data point from a larger financial platform.
Price to book forward of Surgery Partners, Inc. – NASDAQ:SGRY
The TradingView platform provides financial data for Surgery Partners, Inc. (NASDAQ: SGRY), specifically focusing on its price to book forward metric. The platform offers an overview, financials, news, and other data for the company, indicating that the market for SGRY is currently closed with no trades.
Price to sales forward of Surgery Partners, Inc. – NASDAQ:SGRY
This article provides the "Price to sales forward" metric for Surgery Partners, Inc. (NASDAQ: SGRY). It is presented as a financial data point without additional analysis or context within the provided content. The data is made available by FactSet Research Systems Inc.
Price to earnings forward of Surgery Partners, Inc. – FWB:1SP
This page provides financial information for Surgery Partners, Inc. (FWB:1SP) on TradingView, specifically focusing on its forward price-to-earnings ratio. It is a financial data page rather than an analytical article, showing data across various periods.
Surgery Partners, Inc. Actuals & Estimates (NASDAQ:SGRY)
This article provides current financial data and analyst estimates for Surgery Partners, Inc. (NASDAQ:SGRY), including its stock price, market capitalization, earnings, and revenue. It details historical performance, future forecasts, and answers frequently asked questions about investing in the company.
SGRY Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and price target for Surgery Partners, Inc. (SGRY) for 2027, based on analyst opinions. It includes financial data such as current stock price, market capitalization, revenue, and earnings, along with historical performance and volatility. The report also addresses frequently asked questions about SGRY stock, financial reports, and investment advice.
A14YWP Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Surgery Partners, Inc. (A14YWP) stock, based on analyst opinions. It includes financial data such as current stock price, market capitalization, earnings, revenue, and dividend information, while also addressing frequently asked questions about the company's performance and future outlook.
Surgery Partners, Inc. Actuals & Estimates (MUN:1SP)
This article provides financial actuals and estimates for Surgery Partners, Inc. (MUN:1SP), including income statement, balance sheet, and cash flow data, alongside analyst forecasts. It details the company's next earnings report date, past earnings and revenue performance, EBITDA, and employee count, clarifying that the company does not pay dividends.
Tranche Update on Surgery Partners, Inc.'s Equity Buyback Plan announced on March 2, 2026.
Surgery Partners, Inc. reported an update on its equity buyback plan, originally announced on March 2, 2026. Between February 26, 2026, and March 31, 2026, the company did not repurchase any shares or allocate any funds towards the buyback plan. This indicates no activity in the disclosed repurchase program during that specific period.
Why Fast-paced Mover Surgery Partners (SGRY) Is a Great Choice for Value Investors
Surgery Partners (SGRY) is identified as an attractive investment for value investors due to its fast-paced momentum and reasonable valuation. The stock has shown significant price increases over recent weeks and boasts a high beta, indicating strong market movement. Additionally, SGRY has a Zacks Rank #1 (Strong Buy) and trades at a low Price-to-Sales ratio, suggesting potential for further growth.
Unpacking Q1 Earnings: Surgery Partners (NASDAQ:SGRY) In The Context Of Other Outpatient & Specialty Care Stocks
This article analyzes Q1 earnings for outpatient and specialty care stocks, highlighting Surgery Partners (NASDAQ:SGRY) performance. It also compares SGRY with top performer agilon health (NYSE:AGL) and weaker performer U.S. Physical Therapy (NYSE:USPH), along with Select Medical (NYSE:SEM) and LifeStance Health Group (NASDAQ:LFST). The report discusses industry trends, including growth drivers like an aging population and advancements in medical technology, as well as headwinds such as reimbursement cuts and labor shortages.
Surgery Partners Stock - weekly sector check after quiet news flow
Surgery Partners (SGRY) stock has shown modest gains recently with quiet news flow. This article provides a weekly sector check, comparing SGRY's performance against healthcare peers and the broader market, and offers an overview of the company's operations and key financial facts.
SGRY - Outpatient Shifts And CMS Changes Will Expand Surgical Potential
Surgery Partners (SGRY) is positioned for growth due to outpatient surgical shifts and favorable CMS changes, yet faces near-term challenges. Recent analyst re-evaluations, following Q4 results and updated 2026 guidance, show a mixed outlook regarding margins, payer mix, and M&A impact, leading to a slight reduction in the fair value estimate from $18.80 to $17.95. Despite these challenges, long-term growth is still anticipated from strategic investments, regulatory tailwinds, and physician recruitment, with projected annual revenue growth of 5.9% over the next three years.
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent analysis suggests that Surgery Partners (SGRY) stock could be 19% undervalued, with a fair value estimate of about $17.95 compared to its current trading price of $14.55. Despite concerns about slowing sales growth and high debt, the company is well-positioned for future revenue and EBITDA growth due to increased migration of high-acuity surgical procedures to outpatient settings and strategic investments. However, this valuation is vulnerable to persistent anesthesia cost pressures or slower acquisitions.
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Surgery Partners (SGRY) is currently trading at $14.55, which is considered about 19% undervalued compared to a fair value estimate of $17.95. Despite recent concerns regarding slowing sales growth and high debt, the company is well-positioned to capitalize on the shift of surgical procedures to outpatient settings due to its investments in robotics and facility capabilities. The article suggests that while there are risks, the company's rising revenues and improving margins could lead to a healthier earnings profile in the future.
Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?
Wall Street analysts project a 26.14% upside for Surgery Partners (SGRY), with a mean price target of $17.95, indicating potential growth despite varying individual estimates. The article emphasizes that while price targets can be misleading, a consensus in upward earnings estimate revisions, coupled with a Zacks Rank #1 (Strong Buy), suggests a strong positive outlook for the stock's near-term performance. Investors are advised to use price targets cautiously and consider other factors like earnings revisions for investment decisions.
Surgery Partners Inc (SGRY) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Surgery Partners Inc (SGRY), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that the company ranks 30th in the Healthcare Providers & Services industry with a "Buy" trend based on 12 analysts, and details expected revenue and EPS for upcoming quarters.
Wall Street Analysts See a 26.14% Upside in Surgery Partners (SGRY): Can the Stock Really Move This High?
Wall Street analysts project a 26.1% upside for Surgery Partners (SGRY), with a mean price target of $17.95, though the standard deviation indicates varied opinions. Despite the skepticism surrounding analyst price targets, a positive trend in earnings estimate revisions and a Zacks Rank #1 (Strong Buy) rating suggest potential for upside. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
Are Slower Volumes and Higher Debt Quietly Rewriting Surgery Partners’ (SGRY) Growth Narrative?
Recent commentary suggests that Surgery Partners (SGRY) is facing slowing sales volume growth and a more cautious revenue outlook, which combined with high debt levels, amplifies its financial risk. This could reshape the company's investment narrative, moving away from a previously optimistic growth perspective. Investors are left to weigh management's reaffirmed 2026 revenue guidance against weaker stock performance and concerns that debt could limit future earnings power.
Surgery Partners Inc (SGRY) Institutional Confidence
Surgery Partners Inc (SGRY) has an institutional shareholding score of 10.00, ranking 1st in the Healthcare Providers & Services industry. The institutional shareholding proportion has increased by 5.74% quarter-over-quarter, reaching 128.82%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 1.59M shares, which represents 1.39% of shares outstanding.
Surgery Partners Inc (SGRY) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Surgery Partners Inc (SGRY)'s dividend and stock split history. It notes that the company has distributed a total of $0.00 in dividends over the past five years and currently has no dividend or stock split data available. The page also includes current stock price information and market capitalization for SGRY.
Surgery Partners Inc (SGRY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Surgery Partners Inc (SGRY)'s revenue breakdown. For the reported period, patient service revenues constituted 97.51% of the total, amounting to $3.23 billion, while other service revenues made up the remaining 2.49% at $82.40 million. The company has not yet disclosed relevant data for regional revenue and profit contribution.
Surgery Partners | 4: Statement of changes in beneficial ownership of securities-Director Forese Laura L
This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Laura L. Forese, a Director at Surgery Partners. The document details changes in her stock holdings, which is a standard regulatory filing for company insiders. This filing provides transparency regarding director stock transactions.
Surgery Partners Stock Slumps 13% After Company Rejects Bain Capital’s Take-Private Proposal
Surgery Partners' stock fell 13% after its board rejected a take-private offer from Bain Capital at $13.50 per share, deeming the proposal to significantly undervalue the company. The private equity firm, already holding a 48% stake, had initially made the offer in December. Following the rejection, Bain Capital stated it does not plan to pursue the acquisition further at this time.
Surgery Partners vs. Viemed Healthcare: Outpatient Facilities or Home-Based Care in 2026
This article compares Surgery Partners (SGRY) with Viemed Healthcare (VMD), offering insights for investors into two distinct healthcare models: large-scale outpatient facilities and home-based care. Surgery Partners, operating numerous surgical centers, focuses on expanding its presence, leading to revenue growth but short-term net deficits in 2025. Viemed Healthcare specializes in in-home respiratory treatment, showing strong revenue growth and profitability in the same period by catering to the elderly and those with chronic respiratory conditions.
Surgery Partners (SGRY) director awarded 11,670 restricted shares vesting in 2027
Clifford G. Adlerz, a director at Surgery Partners (SGRY), has been awarded 11,670 restricted shares of common stock as part of the company's compensation program. The shares, granted at a reference price of $13.71 per share, are not an open-market purchase and will fully vest on June 5, 2027. Following this grant, Adlerz's direct holdings in Surgery Partners increased to 69,104 shares.
[Form 4] Surgery Partners, Inc. Insider Trading Activity
This article details an insider trading activity for Surgery Partners, Inc. (SGRY) filed on a Form 4. The report indicates that insider HENDRIX BLAIR E acquired 11,670 shares of common stock at $13.71, valued at approximately $160K, with shares vesting on June 5, 2027. Following this transaction, Hendrix Blair E now directly owns 18,531 shares of common stock.
Director Laura Forese awarded 11,670 Surgery Partners (SGRY) shares as equity grant
Director Laura L. Forese of Surgery Partners (SGRY) was awarded 11,670 shares of common stock as an equity grant, valued at a reference price of $13.71 per share. These shares are compensation related and will vest on June 5, 2027. Following this grant, her direct holdings in the company amount to 18,531 shares.
Surgery Partners (SGRY) grants 11,670-share stock award to director
Surgery Partners (SGRY) director Dean Lloyd H was granted 11,670 shares of common stock as equity compensation, valued at $13.71 per share. This transaction was reported in a Form 4 SEC filing, indicating the shares are directly held and are scheduled to vest on June 5, 2027. Following this award, his direct holdings in Surgery Partners amount to 11,670 shares.
Director John Deane receives 11,670 Surgery Partners (SGRY) share grant
John A. Deane, a director at Surgery Partners, Inc. (SGRY), has been granted 11,670 shares of Common Stock as equity compensation. These shares are valued at $13.71 each and are set to vest on June 5, 2027. Following this grant, Deane directly holds 45,922 shares of the company.
Equity grant gives Surgery Partners (NASDAQ: SGRY) director 11,670 shares
Surgery Partners, Inc. director Brent Turner was granted 11,670 shares of Common Stock at $13.71 per share, as reported in a Form 4 filing. This compensation-related award increases his direct holdings to 86,594 shares, which are scheduled to vest on June 5, 2027. The transaction was a share grant, not an open-market purchase.
Surgery Partners (SGRY) holders re-elect directors, approve pay and ratify EY
Surgery Partners, Inc. (SGRY) shareholders, as of the April 8, 2026 record date, re-elected Class II directors Devin O'Reilly, Brent Turner, and Laura L. Forese, M.D., to serve until the 2029 annual meeting. They also approved the company's executive compensation program on a non-binding advisory basis and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The 8-K filing details the voting results for each proposal.
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $17
TD Cowen has reinforced its "Buy" rating for Surgery Partners (SGRY.US) but has adjusted its price target downwards to $17 from the previous $20. This indicates continued confidence in the company's prospects despite a revision in the valuation outlook.
Surgery Partners stock (US85701Q1031): Earnings date in focus ahead of August report
Surgery Partners (SGRY) is expected to report its second-quarter earnings on August 4, 2026. The company, which operates ambulatory surgery centers, is watched by investors for its sensitivity to outpatient procedure volumes and reimbursement trends in the US healthcare market. The upcoming report will be crucial for insights into same-center performance, reimbursement, and demand for elective procedures.
Surgery Partners Inc stock (US85701Q1031): earnings momentum and M&A reshape outlook
Surgery Partners Inc (SGRY) recently reported strong quarterly results, driven by increased surgical case volumes and successful integration of past acquisitions within the US outpatient surgery market. The company is strategically focused on shifting procedures from inpatient to outpatient settings, capitalizing on favorable demographic trends and expanding into higher-acuity procedures like orthopedics and cardiology. Future performance hinges on continued case migration, effective acquisition integration, and managing regulatory and reimbursement changes in the evolving healthcare landscape.
[SCHEDULE 13G/A] Surgery Partners, Inc. Amended Passive Investment Disclosure
Pentwater Capital Management has filed an amended Schedule 13G/A, disclosing beneficial ownership of 12,655,000 shares of Surgery Partners, Inc. (SGRY), which represents 9.7% of the company's common stock. The filing indicates a passive investment intent with shared voting and dispositive power. Matthew Halbower is identified as a reporting person through his role with the Investment Manager.
Surgery Partners Delivered Solid Q1 Beat Amid Stabilizing Portfolio, RBC Says
RBC Capital Markets highlighted Surgery Partners' strong first-quarter performance, noting a solid beat on earnings and a stabilizing portfolio. The company is reportedly making progress in addressing its physician staffing needs, which is expected to support future growth. RBC reiterated an Outperform rating, increasing the price target to $46.
A Look At Surgery Partners (SGRY) Valuation After Reaffirmed Guidance And Positive First Quarter Results
Surgery Partners (SGRY) recently reported strong Q1 results, with revenue growth and a narrower loss, while reaffirming full-year guidance. Despite negative long-term share returns, the company is seen as potentially undervalued, trading at a discount to analyst targets. The stock's valuation hinges on continued margin expansion, revenue growth, and effective execution of M&A and portfolio optimization strategies.
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY)
Surgery Partners (SGRY) reported stronger-than-expected Q1 2026 results with narrower net losses and reaffirmed full-year revenue guidance, despite a significant debt load. The company's investment narrative continues to hinge on sustained outpatient surgery growth and operational execution to manage costs and achieve profitability targets. This performance may influence analyst forecasts, which currently vary widely on the company's long-term earnings potential.
Number of shareholders of Surgery Partners, Inc. – LSX:A14YWP
This article provides details about the number of shareholders for Surgery Partners, Inc. (LSX:A14YWP) on TradingView. It indicates that specific shareholder data is available for a given period, along with change values and percentages. The content is primarily a data placeholder within the TradingView platform, noting market and reference data sources.
Surgery Partners outlines 2026 revenue of $3.35B-$3.45B and adjusted EBITDA of at least $530M as portfolio optimization targets mid-2026 announcement
Surgery Partners (NASDAQ:SGRY) has provided its financial outlook for 2026, projecting revenue between $3.35 billion and $3.45 billion and adjusted EBITDA of at least $530 million. The company is actively engaged in a portfolio optimization strategy, with an update expected by mid-2026, aimed at enhancing financial performance and strategic alignment. These targets highlight the company's growth trajectory and efforts to streamline its operations for future profitability.
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY)
Surgery Partners (SGRY) recently reported stronger-than-expected first-quarter results, with revenue rising to US$810.9 million and a narrowing net loss. The company reaffirmed its full-year 2026 revenue guidance of US$3.35 billion to US$3.45 billion, despite its US$3.70 billion debt load. While the improved adjusted earnings and reaffirmed guidance are positive signals, the long-term investment narrative still hinges on balancing revenue growth from outpatient surgeries against persistent losses and high interest costs.
Surgery Partners price target raised to $17 from $15 at Jefferies
Jefferies has increased its price target for Surgery Partners (SGRY) to $17 from $15, maintaining a Buy rating. The adjustment follows the company's strong first-quarter performance, which occurred despite weather-related challenges affecting healthcare providers. Jefferies anticipates a gradual improvement in payor mix issues throughout the year.
